We assume that if the entire CCR2/CCL2 signaling axis is inflicted by antibody treatment, tumor growth is inhibited, while specific knockout of tumor microenvironmental cells by using a Ccr2-/- transgenic mice leads to enhanced glioma progression. This evidence concerns the gene CCR2 and central nervous system cancer.